A Phase I, Randomized, Double-blind, Single-dose, Partial-replicate, 3-way Cross-over Study to Assess the Total Systemic Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI HFO Compared With BGF MDI HFA
Latest Information Update: 19 May 2023
At a glance
- Drugs Budesonide/formoterol/glycopyrrolate (Primary) ; Budesonide/formoterol/glycopyrrolate (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 16 May 2023 Status changed from recruiting to completed.
- 10 Nov 2022 New trial record